At SignaGen Laboratories, we prioritize the rights and ownership of our customers in every aspect of lentiviral vector development. All intellectual property (IP) generated during the design, cloning, and production of lentiviral vectors—including the final packaged vectors and any cloned cis constructs—remains the exclusive property of the customer. Whether the project involves the use of an end-user–provided gene of interest (GOI) or a synthesized fragment produced at SignaGen, the customer retains full control over all sequences, designs, and related IP. SignaGen serves solely as a service provider, executing vector design, cloning, validation, and packaging according to the customer’s specifications while ensuring the highest standards of quality and reproducibility. By maintaining full IP ownership, customers are free to use, modify, or commercialize their lentiviral vectors without restrictions or claims from SignaGen. This approach fosters trust, transparency, and collaboration, allowing researchers to advance their projects with confidence, knowing that all proprietary information, designs, and resulting lentivirus products are fully secured under their ownership from the initial concept through final delivery.

To learn more, please contact us at info@signagen.com